HCA · Q4 2025 Earnings

Cautious

HCA Healthcare

Reported January 27, 2026

30-second summary

HCA closed FY2025 above the high end of its raised revenue and EPS guide ($75.6B revenue, $28.33 GAAP EPS) and delivered the FY2026 numeric guide it deferred last quarter — but the guide bakes in a $600–900M adverse EBITDA hit from health-exchange dynamics and a $250–450M decline in supplemental payments, offset only partially by a $400M resiliency program. Management paired the cautious operating guide with a $10B buyback authorization and a higher capex range of $5.0–5.5B, a striking capital-deployment posture given the quantified headwinds.

Headline numbers

EPS

Q4 FY2025

$8.01

Revenue

Q4 FY2025

$19.51B

+6.7% YoY

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$19.51B	+6.7%	$19.16B	+1.8%
EPS	$8.01	—	$6.96	+15.1%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	FY2025	$75.0 billion to $76.5 billion	$75.6 billion	+$0.1 billion above high end of prior guide	Beat
EPS (diluted, GAAP)	FY2025	$27.00 to $28.00	$28.21	+$0.21 above high end of prior guide	Beat
Net Income Attributable to HCA Healthcare, Inc.	FY2025	$6.50 billion to $6.72 billion	$6.495 billion	-$0.005 billion (essentially at lower bound of prior guide)	Beat
Adjusted EBITDA	FY2025	$15.25 billion to $15.65 billion	—	—	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	FY2026	$76.500 billion to $80.000 billion	+1.2% to +5.8% YoY
EPS (diluted, GAAP)	FY2026	$29.10 to $31.50	+3.2% to +11.7% YoY
Adjusted EBITDA	FY2026	$15.550 billion to $16.450 billion	—
Net Income Attributable to HCA Healthcare, Inc.	FY2026	$6.495 billion to $7.035 billion	—
Capital Expenditures (excluding acquisitions)	FY2026	$5.0 billion to $5.5 billion	—
Equivalent Admissions Growth	FY2026	2% to 3%	—
Cash Flow from Operations	FY2026	$12 billion to $13 billion	—
Adjusted EBITDA Margin	FY2026	Slightly above 20%	—

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Adjusted EBITDA	$4.114B (Q4 2025)
Adjusted EBITDA Margin	21.1%
Same Facility Emergency Room Visits Growth	0.5%
Same Facility Inpatient Surgeries Growth	0.0%
Same Facility Outpatient Surgeries Growth	-0.5%
Operating Cash Flow	$2.359B (Q4 2025)
Hospitals Operated	190
Ambulatory Sites of Care	~2,500

Management tone

Q1-2025 policy risk emerges → Q2-2025 volume guide cut, resiliency deferred → Q3-2025 EPS raised, 2026 explicitly deferred and volume guide quietly withdrawn → Q4-2025 policy headwinds quantified, resiliency sized, capital deployment accelerated.

From "we will provide updates at the appropriate times" to specific dollar ranges built into the guide. Three quarters ago management framed policy risk as evolving and unquantifiable. This quarter every major exposure carries a number: $600–900M EBITDA impact from exchanges, $250–450M decline in supplemental payments, $400M resiliency offset. The shift from vague monitoring to "the rate at which we are reducing the cost structure will produce approximately $400 million in incremental cost savings in 2026" reflects management has stopped trying to talk around the headwinds and is now modeling them explicitly. The trade-off: the credibility of the resiliency offset is now front and center, and at $400M vs $600–900M of headwind, even successful execution leaves a $200–500M EBITDA gap.

From "supplemental payments as net positive contributor" a year ago to "decline in supplemental payment programs net benefit between $250 million and $450 million" this quarter. A year ago supplemental payments were a structural Medicaid offset; now management is guiding a $250–450M YoY decline driven by Tennessee reverting to four quarters from six, a Texas pause, and the one-time nature of the Virginia retro. The Q3 brief flagged the run-rate vs catch-up distinction as the key 2026 baseline question — this quarter resolves it negatively.

From "we will limit our early thoughts for 2026" last quarter to a $10B buyback authorization this quarter despite explicitly quantified headwinds. The capital-deployment posture is the most aggressive forward signal in the print: capex range raised to $5.0–5.5B from ~$5.0B, a new $10B buyback authorization with commitment to complete "the majority of the existing authorization in 2026," all announced alongside $600–900M of acknowledged EBITDA headwinds. Management is using the balance sheet to bridge a softer operating year — defensible given FY2026 OCF guidance of $12–13B, but a clear signal that EPS growth in 2026 leans heavily on share count reduction rather than operating leverage.

Volume framing softened from achievement to assumption. FY2025 delivered 2.5% equivalent admissions growth; FY2026 reaffirms "long-term 2% to 3% growth range." Hazen anchored it as "we believe our core business remains strong with forecasted volumes in our long-term 2% to 3% growth range" — same number HCA has cited for years, but with surgery cases reversing negative in Q4 (-0.5% outpatient, 0.0% inpatient) and ER visits decelerating to +0.5%, the 2–3% guide now sits at the top of what the recent run-rate supports. The withdrawal of the numeric guide in Q3 and its restoration this quarter as a "long-term range" keeps the accountability deliberately soft.

Margin posture shifted from "expansion runway" to "slightly above 20%." Q4 delivered 21.1% adjusted EBITDA margin; FY2025 implied ~20.6%; FY2026 guide is "slightly above 20%." Even at the high end of the EBITDA range ($16.45B) on the low end of revenue ($76.5B), margin computes to ~21.5%; at the low end of EBITDA on the high end of revenue, margin is ~19.4%. Management's "slightly above 20%" framing centers the guide near the bottom of that band — a tacit acknowledgment that the $400M resiliency offset does not fully cover the $600–900M exchange headwind.

Recurring themes management leaned on this quarter:

Policy headwinds quantified and incorporated into guidanceResiliency program as offset mechanism to regulatory challengesVolume growth moderating but stable within 2-3% rangeSupplemental payments declining as revenue contributorCapital deployment acceleration despite macro uncertaintyDigital transformation and technology investment as long-term strategic priority

Risks management surfaced:

Health insurance exchange volume and revenue pressure ($600M-$900M adverse impact)Supplemental payment program decline ($250M-$450M headwind)Enhanced premium tax credit expiration impactAdministrative reforms affecting insurance exchange dynamicsPotential impact from grandfathered applications (noted as excluded from guidance)

Q&A highlights

Anne Hines · Mizuho

Requested detailed breakdown of the $400 million resiliency program, its four key areas of focus, and management confidence in executing throughout 2026, including timing of potential volume loss from ACA subsidy expiration.

Management detailed four key focus areas: revenue integrity, digital transformation with AI/automation, and shared service platform leverage. Program spans corporate, hospital operations, and shared services with planned efforts in capacity management (throughput, length of stay), labor efficiency, supply cost actions, and operating cost controls. Management expressed confidence in executing $400M savings. Also provided detailed modeling of $600-900M EBITDA impact range, assuming 15-20% decline in exchange volumes with migration to either employee-sponsored insurance or uninsured status.

$400 million incremental cost savings target for 2026 vs 202515-20% assumed decline in health exchange volumes15-20% of declining volumes assumed to migrate to employee-sponsored insuranceRemaining exchange volume assumed to migrate to uninsured with ~30% utilization decline

Andrew Mock · Barclays

Inquired about year-over-year decline in outpatient surgeries, its drivers across different payer categories, and whether specific service lines were under pressure.

Management reported same-facility outpatient surgery cases down ~50 basis points in Q4 vs prior year (hospitals flat, ASCs down ~1.5%). Primary driver identified as Medicaid payer mix headwind and decline in lower-intensity cases like ENT. Despite volume decline, net revenue and earnings grew due to favorable payer mix elsewhere. Management emphasized ongoing outpatient facility expansion and future growth trajectory.

Outpatient surgery same-facility cases down ~50 basis points Q4 YoYHospital outpatient surgery cases flat YoYASC outpatient surgery cases down ~1.5% YoY~100 outpatient business units added in 2025

A.J. Rice · UBS

Asked about underlying expense assumptions embedded in guidance across supplies, operating expenses, and professional fees, and identified margin improvement opportunities for 2026.

Management indicated stable margin expectations at midpoint of guidance range for 2026 vs 2025. Expects mostly stable operating cost trends consistent with prior years. Anticipates physician cost pressures in high single digits (growth). Contract labor as % of salaries/wages at ~4.2% in Q4, consistent with current run rate. Resiliency plan embedded in guidance to offset exchange headwinds and reflect strong cost/operating leverage.

Stable margin expectations for 2026 vs 2025Operating costs expected to remain mostly stablePhysician cost pressures expected in high single digits growthContract labor ~4.2% of salaries/wages in Q4 2025

Kevin Fishbeck · Bank of America

Asked for clarification on collection rates for bronze vs silver exchange plans and whether HCA can sustain margins above 20% given cost savings capabilities.

Management did not provide specific collection rate percentages but noted bronze enrollees have lower collection rates than silver based on historical experience. Regarding margin outlook, management indicated comfort maintaining long-term performance targets given strong demand in markets, resiliency programs, and digital transformation initiatives, but declined to project margins above 20% specifically, instead referencing long-term confidence without quantifying potential upside.

Bronze exchange enrollees have lower collection rates than silverManagement comfortable maintaining long-term performance targets2026 guidance reflects ~20% adjusted EBITDA margin (stable vs 2025)Long-term confidence in ability to maintain performance over time given demand, resiliency, and digital transformation

Whit Mayo · LeRinc Partners

Asked about digital initiatives with payers around data exchange, dispute resolution, and how those efforts manifest in revenue cycle improvements, collections, and reduced payer friction.

Management described multi-year engagement with major payers focused on digital integration including electronic data exchange, administrative simplification, and dispute resolution. Noted efforts aimed at making member/patient experience better and digitalizing workflows. Highlighted Q4 working capital improvements, particularly reduction in days sales outstanding (DSO), especially in Q4, reflecting benefits of payer data sharing. Emphasized these efforts yield claims paid more timely and help mitigate denials/disputes benefiting both parties.

Series of engagements launched with major payers on digital integrationFocus areas: electronic data exchange, administrative simplification, dispute resolutionQ4 showed nice reduction in days in accounts receivableBenefits include timelier claims payment and mitigation of denials and disputes

Answers to last quarter's watch list

2026 guidance scope on the Q4 call — Resolved positively on disclosure: management delivered a full numeric FY2026 guide across revenue ($76.5–80B), EBITDA ($15.55–16.45B), GAAP EPS ($29.10–31.50), net income, capex, OCF, and equivalent admissions growth — substantially more comprehensive than the qualitative deferral Q3 implied. The credibility question shifts from "will they guide" to "will the $400M resiliency offset close the gap against $600–900M of headwinds.".

Resolved positively

Run-rate supplemental payments in Q4 and FY2026 — Resolved negatively: management guided FY2026 supplemental payments to decline $250–450M YoY vs FY2025, citing Tennessee reverting from six quarters of recognition to four, the Texas program pause, and the one-time nature of the Virginia retro. The clean run-rate is materially below FY2025's elevated level — confirming the Q3 brief's concern that catch-up recognition inflated the FY2025 baseline.

Resolved negatively

Pending grandfathered DTP approvals (FL, GA, VA) — Not resolved: management noted FY2026 guidance "does not include any potential impact in 2026 from additional approvals of grandfathered applications" — preserving the upside optionality but indicating no green-lights have come through.

Continue monitoring

EPTC extension legislative outcome — Resolved negatively: the FY2026 guide explicitly cites "the expiration of the enhanced premium tax credits" alongside "administrative reforms enacted in 2025" and "the One Big Beautiful Bill Act" as drivers of the $600–900M EBITDA headwind. The legislative outcome went against HCA.

Resolved negatively

Equivalent admissions in Q4 vs the withdrawn 2–3% range — Resolved positively: Q4 same-facility equivalent admissions grew 2.5%, comfortably inside the 2–3% range, and FY2025 came in at 2.4% same-facility. The Q3 concern that the guide withdrawal masked a hidden cut did not materialize.

Resolved positively

EBITDA margin trajectory — Resolved with caveats: Q4 adjusted EBITDA margin came in at 21.1% (+90bps YoY), holding above 20% even as supplemental payment run-rate normalized. But FY2026 guidance frames margin as "slightly above 20%" — implying compression from FY2025's ~20.6% level as exchange headwinds bite.

Resolved negatively

DTP baseline normalization — Not resolved: the FY2026 guide expresses the change as a $250–450M YoY decline rather than restating an absolute baseline. The structural sizing question remains open.

Continue monitoring

What to watch into next quarter

Q1 2026 progress on the $400M resiliency target — Management committed to incremental cost savings spread across revenue integrity, digital, and shared services. Watch for a quantified Q1 contribution and whether full-year run-rate is tracking toward $400M or above. Slippage below ~$300M annualized would force margin compression worse than "slightly above 20%."

Exchange volume decline relative to 15–20% modeled assumption — Q1 will be the first quarter of post-EPTC enrollment dynamics. If exchange equivalent admissions decline more than 20%, the $600–900M EBITDA impact range moves toward or above the high end and the $400M resiliency offset becomes inadequate.

Surgery case trajectory — Outpatient cases reversed to -0.5% in Q4 after Q3's +1.1% turn. Watch whether this is Medicaid mix noise or a structural deceleration. Two consecutive quarters of negative outpatient surgery growth would call the FY2026 2–3% equivalent admissions guide into question.

Buyback pacing vs. operating cash flow — Management committed to completing "the majority" of the existing buyback in 2026 plus the new $10B authorization. With OCF guided at $12–13B and capex at $5.0–5.5B, FCF supports roughly $7B of returns. Pacing materially above this implies balance-sheet leverage to fund the program.

Pending DTP approvals (Florida, Georgia, Virginia) — Any approval represents pure upside to the FY2026 guide and would be the cleanest positive catalyst available. Watch CMS announcements through Q1/Q2.

Adjusted EBITDA margin against "slightly above 20%" framing — The guide-midpoint math computes to ~20.5%. Anything sustainably below 20% on a quarterly basis would signal the resiliency program is failing to offset exchange and supplemental headwinds.

Sources

HCA Healthcare Q4 2025 press release, filed January 27, 2026: https://www.sec.gov/Archives/edgar/data/860730/000119312526023323/hca-ex99_1.htm
Q4 2025 earnings call commentary from Sam Hazen (CEO) and Mike Marks (CFO), including Q&A with Anne Hines (Mizuho), Andrew Mock (Barclays), A.J. Rice (UBS), Kevin Fishbeck (Bank of America), and Whit Mayo (Leerink Partners).
Tapebrief Q3 2025 and Q2 2025 HCA briefs (prior watch list and guidance baselines).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.